AU2021227279A1 - Anti-adrenomedullin (ADM) binder for use in therapy of patients in shock - Google Patents

Anti-adrenomedullin (ADM) binder for use in therapy of patients in shock Download PDF

Info

Publication number
AU2021227279A1
AU2021227279A1 AU2021227279A AU2021227279A AU2021227279A1 AU 2021227279 A1 AU2021227279 A1 AU 2021227279A1 AU 2021227279 A AU2021227279 A AU 2021227279A AU 2021227279 A AU2021227279 A AU 2021227279A AU 2021227279 A1 AU2021227279 A1 AU 2021227279A1
Authority
AU
Australia
Prior art keywords
adm
antibody
adrenomedullin
scaffold
shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021227279A
Other languages
English (en)
Inventor
Andreas Bergmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adrenomed AG
Original Assignee
Adrenomed AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adrenomed AG filed Critical Adrenomed AG
Publication of AU2021227279A1 publication Critical patent/AU2021227279A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021227279A 2020-02-27 2021-03-01 Anti-adrenomedullin (ADM) binder for use in therapy of patients in shock Pending AU2021227279A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20159913 2020-02-27
EP20159913.1 2020-02-27
EP20206317 2020-11-06
EP20206317.8 2020-11-06
PCT/EP2021/055068 WO2021170880A2 (fr) 2020-02-27 2021-03-01 Liant anti-adrénomédulline (adm) destiné à être utilisé en thérapie pour des patients en état de choc

Publications (1)

Publication Number Publication Date
AU2021227279A1 true AU2021227279A1 (en) 2022-10-20

Family

ID=74732950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021227279A Pending AU2021227279A1 (en) 2020-02-27 2021-03-01 Anti-adrenomedullin (ADM) binder for use in therapy of patients in shock

Country Status (11)

Country Link
US (1) US20230250166A1 (fr)
EP (1) EP4110812A2 (fr)
JP (1) JP2023515985A (fr)
KR (1) KR20220145898A (fr)
CN (1) CN115244081A (fr)
AU (1) AU2021227279A1 (fr)
BR (1) BR112022016843A2 (fr)
CA (1) CA3169447A1 (fr)
IL (1) IL295951A (fr)
MX (1) MX2022010564A (fr)
WO (1) WO2021170880A2 (fr)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
CA2124967C (fr) 1991-12-17 2008-04-08 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
MXPA04001804A (es) 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
US6864237B2 (en) * 2002-05-17 2005-03-08 Ping Wang Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US20070082363A1 (en) 2003-04-25 2007-04-12 Lydie Bougueleret Secreted polypeptide species reduced cardiovascular disorders
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
EP1800131A2 (fr) 2004-09-09 2007-06-27 Bayer HealthCare AG Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2006032436A2 (fr) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Utilisation de microproteines en tant qu'inhibiteurs d'une tryptase
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
US9376477B2 (en) 2009-08-27 2016-06-28 Covagen Ag IL-17 binding compounds and medical uses thereof
BR112012014194A2 (pt) 2009-12-14 2017-01-10 Scil Proteins Gmbh um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos
DK2580236T3 (da) 2010-06-08 2019-06-11 Pieris Pharmaceuticals Gmbh Muteiner af tåre-lipocalin, der binder til il-4-r-alfa
EP2780370B1 (fr) 2011-11-16 2019-09-25 AdrenoMed AG Anticorps anti-adrénomédulline (adm) ou fragment d'anticorps anti-adm ou échafaudage non-ig anti-adm pour l'application thérapeutique en cas d'une maladie aiguë ou d'un état aigu d'un patient pour la stabilisation de la circulation
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
JP6321545B2 (ja) 2011-11-16 2018-05-09 アドレノメト アクチェンゲゼルシャフト 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
DK3553084T3 (da) 2011-11-16 2023-02-20 Adrenomed Ag Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand
LT2780371T (lt) 2011-11-16 2019-05-27 Adrenomed Ag Adrenomeduliną (adm) atpažįstantis antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne ig struktūros karkasas, skirti paciento, sergančio lėtine arba ūmia liga, skysčių pusiausvyros reguliavimui
EP4417218A2 (fr) 2016-04-21 2024-08-21 4TEEN4 Pharmaceuticals GmbH Procédés de détermination de dpp3 et procédés thérapeutiques

Also Published As

Publication number Publication date
KR20220145898A (ko) 2022-10-31
CA3169447A1 (fr) 2021-09-02
WO2021170880A3 (fr) 2021-10-28
MX2022010564A (es) 2022-11-30
JP2023515985A (ja) 2023-04-17
EP4110812A2 (fr) 2023-01-04
BR112022016843A2 (pt) 2022-10-11
WO2021170880A2 (fr) 2021-09-02
US20230250166A1 (en) 2023-08-10
IL295951A (en) 2022-10-01
CN115244081A (zh) 2022-10-25

Similar Documents

Publication Publication Date Title
US11673949B2 (en) Method of modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-ADM antibody or fragment thereof that specifically binds to mature human ADM
EP2780370B1 (fr) Anticorps anti-adrénomédulline (adm) ou fragment d'anticorps anti-adm ou échafaudage non-ig anti-adm pour l'application thérapeutique en cas d'une maladie aiguë ou d'un état aigu d'un patient pour la stabilisation de la circulation
CA3148275A1 (fr) Orientation de therapie et/ou surveillance de therapie permettant le traitement d'un choc
US20230104578A1 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
US20230193348A1 (en) Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
US20230250166A1 (en) Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
EP3897686A2 (fr) Guidage thérapeutique et/ou surveillance thérapeutique pour un traitement avec un agoniste du récepteur de l'angiotensine et/ou un précurseur de celui-ci
EP4345109A1 (fr) Liant anti-adrénomédulline (adm) destiné à être utilisé dans la thérapie de patients pédiatriques atteints de cardiopathie congénitale
WO2024023369A1 (fr) Anticorps anti-adrénomédulline (adm) ou fragment d'anticorps anti-adm ou échafaudage non-ig anti-adm destiné à être utilisé en thérapie ou prévention du choc
WO2024126793A1 (fr) Inhibiteur de dpp3 pour l'amélioration de la fonction pulmonaire chez des patients gravement malades
WO2024023368A1 (fr) Prédiction d'augmentation de dpp3 chez un patient souffrant d'un choc septique
CA3207969A1 (fr) Anticorps anti-adrenomedulline (adm) ou fragment d~anticorps anti-adm ou echafaudage anti-adm ne provenant pas de l~immunoglobuline aux fins d~utilisation dans la therapie ou la prevention des chocs et prediction d~une augmentation de dpp3 chez un patient gravement atteint